Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
05-Aug-2009 -
Eiger BioPharmaceuticals, Inc. announced that it has licensed the exclusive worldwide rights to novel Hepatitis C Virus (HCV) technology from Stanford University. This technology, discovered in the lab of Stanford scientist and Eiger founder Dr. Jeffrey Glenn, M.D., Ph.D., is focused on a variety ...
drug resistance
hepatitis C
inhibitors
+2